A Human Immunodeficiency Virus Screening Algorithm to Address the High Rate of False-Positive Results in Pregnant Women in Japan by Shima-Sano, Takako et al.
A Human Immunodeficiency Virus Screening Algorithm
to Address the High Rate of False-Positive Results in
Pregnant Women in Japan
Takako Shima-Sano
1,2*, Rika Yamada
3, Kazuyo Sekita
4, Raleigh W. Hankins
4, Hiromasa Hori
5, Hiroshi
Seto
6, Koji Sudo
1,9, Makiko Kondo
1, Kazuo Kawahara
2, Yuki Tsukahara
7, Noriyuki Inaba
8, Shingo Kato
9,
Mitsunobu Imai
1
1Division of Microbiology, Kanagawa Prefectural Institute of Public Health, Kanagawa, Japan, 2Department of Health Care Management and Planning, Graduate School
of Medical and Dental Science, Tokyo Medical and Dental University, Tokyo, Japan, 3Center for Women’s and Children’s Health, Department of Obstetrics and
Gynecology, Ishikawa Prefectural Central Hospital, Ishikawa, Japan, 4Health Sciences Research Institute, Incorporated, Kanagawa, Japan, 5Hori Maternity Hospital,
Kanagawa, Japan, 6Seto Hospital, Saitama, Japan, 7Division of Obstetrics, National Center for Child Health and Development, Tokyo, Japan, 8Department of Obstetrics
and Gynecology, Dokkyo Medical University, Tochigi, Japan, 9Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan
Abstract
Background: Prenatal human immunodeficiency virus (HIV) testing is essential for the prevention of mother-to-child
transmission. However, false-positive results of screening testing are a concern as they may cause unnecessary emotional
stress to pregnant women waiting for confirmatory test results. In regions with an extremely low prevalence, the positive
predictive values of screening are unacceptably low rate. Here, we propose a HIV screening algorithm consisting of serial
two fourth-generation enzyme immunoassays to reduce the number of false-positive screening results.
Methodology/Principal Findings: When 6461 pregnant women presenting to two maternity hospitals located in the Tokyo
metropolitan area of Japan from September, 2004 to January, 2006 were tested using Enzygnost HIV Integral as a first
screening test, 27 showed positive reactions. When these positive reaction samples were tested using VIDAS HIV DUO Quick
as a second screening test, only one of them had a positive reaction, and the remaining 26 were nonreactive. Confirmatory
Western blots and nucleic acid amplification test also showed that one was positive and the remaining 26 were negative;
the subject who was positive with the confirmatory tests was identical to the subject who was positive with the second
screening test. Thus, by adding the second screening test, the false-positive rate was improved from 0.4% to 0%, and the
positive predictive value from 3.7% to 100%, compared with the single screening test.
Conclusion: By applying our serial screening algorithm to HIV testing in maternity hospitals, many uninfected pregnant
women would not need to receive confirmatory tests and be subjected to emotional turmoil while waiting for their
confirmatory test results. This algorithm would be suitable for HIV testing of pregnant women living in low prevalence
regions such as Japan.
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Introduction
The human immunodeficiency virus (HIV) epidemic in Japan is
still at a low level compared with other developed countries, but the
number of newly identified infections is increasing every year. For
earlier detection and clinical and preventive services, much effort is
made to implement voluntary HIV counseling and testing in a
variety of health-care settings including public health centers, STD
clinics,andoutreachmedicalservices.Accordingtothereportofthe
National AIDS Surveillance Committee, 13,894 persons with HIV/
AIDS were reported between 1985 and 2007, and 1,500 new cases
were reported in 2007 alone [1]. The HIV prevalence in Japan was
estimated at 0.008% in 2007 [2]. Of all the HIV-infected persons
reported in Japan, 71.0% were Japanese men; 11.4% were non-
Japanese men; 6.2% were Japanese women; and 11.4% were non-
Japanese women. Currently, about 70% of the Japanese men with
HIV infection are men who have sex with men.
Although the HIV prevalence in women is very low in Japan
(about 0.004%), universal HIV testing has been performed for
pregnant women to prevent mother-to-child transmission since 1999
PLoS ONE | www.plosone.org 1 February 2010 | Volume 5 | Issue 2 | e9382[3]. Nationwide questionnaire surveys on HIV testing in pregnant
women are conducted every year. The HIV testing rate has gradually
increased from 73.2% in 1999 to 97.2% in 2007. Over the 21 years
between 1987 and 2007, mother-to-child transmission has occurred
in only one in 219 (0.5%) HIV-infected pregnant women who
received both antiretroviral therapy (ART) and a cesarean section,
one in 17 (6%) women who had a cesarean section without ART, and
14 in 36 (39%) women who delivered vaginally [3].
Although prenatal HIV testing is essential for the prevention of
mother-to-child transmission, there are concerns about false-positive
results of screening tests [4,5]. Positive test results may cause anxiety
of HIV infection and emotional stress in pregnant women waiting for
confirmatory test results. Some severe cases were covered by the mass
media in 2007, leading to an official notification on the frequent
observation of HIV false-positive screening results from the Ministry
of Health, Labour and Welfare of Japan [6].
There has been little study on the rate of false-positive results in
HIV screening testing of pregnant women in Japan. Thus, we
conducted a prospective study at two maternity hospitals in the
Tokyo metropolitan area to evaluate the performance of screening
test, including the prevalence, false-positive rate, and positive
predictive value, and proposed a new HIV screening algorithm
composed of two serial tests to enable a substantial reduction in the
number of false-positive results at this stage.
Materials and Methods
Study Setting
The study was conducted from September, 2004 to January,
2006 in two maternity hospitals located in the Tokyo metropolitan
area. Each of the hospitals conducts more than 1,000 deliveries
each year.
HIV Testing
Blood samples were initially tested using Enzygnost HIV Integral
(SiemensHealthcareDiagnostics,Deerfield,Illinois,USA),afourth-
generation enzyme-linked immunosorbent assay with the ability to
detectHIV-1gp41 antibody,HIV-2gp36antibody,andHIV-1p24
antigen at a reference laboratory of the Health Science Research
Institute Inc. (Yokohama, Japan). The Enzygnost HIV Integral can
test 880 samples during each run lasting 240 min. The samples that
tested positive in the initial screening were subjected to a secondary
screening test and confirmatory tests, which were conducted at the
Kanagawa Prefectural Institute of Public Health. The second
screening test was performed using VIDAS HIV DUO Quick
(bioMe ´rieux, Marcy l’Etoile, France), a fourth-generation enzyme-
linked fluorescent assay with the ability to detect HIV-1 gp160
antibody, HIV-2 gp36 antibody, and HIV-1 p24 antigen. The
VIDAS HIV DUO Quick can test 60 samples during each run
lasting 80 min. Confirmatory tests were performed using Western
blot tests (Lab blot 1 and Lab blot 2; Bio-Rad Laboratories,
Hercules, California, USA), and a nucleic acid amplification test
(NAT), Amplicor HIV-1 Monitor test version 1.5 (Roche Molecular
Systems, Branchburg, New Jersey, USA). HIV typing was
performed using SERODIANHIV-1/2 PA (Fujirebio, Tokyo,
Japan). All the tests were conducted and interpreted as recom-
mended by the manufacturers.
Samples for Evaluating the Sensitivity of the Screening
Tests
Ten HIV-1 seroconversion panels (PRB 936, 937, 938, 939(E),
945, 951, 952, 953, 954, and 955) and two samples from HIV p24
Antigen Mixed Titer Performance panels (PRA 201-05 and 201-
17) were obtained from SeraCare Life Sciences (formerly Boston
Biomedica, West Bridgewater, Massachusetts, USA). Seroconver-
sion panels were used to evaluate the sensitivity in the early phase
of infection. Three samples (PRB 936-04, PRA 201-05, and PRA
201-17) were diluted twofold serially with HIV negative human
pooled plasma and were used to evaluate the antigen detection
sensitivity of the enzyme immunoassay (EIA).
Screening Algorithm
We proposed an algorithm (Fig. 1) to reduce the number of false-
positive screening results in prenatal HIV testing. In our algorithm,
eachbloodsample is testedserially with two EIA tests that should be
highly sensitive and have different detection formats. The first
screening test was performed on the day or next day of blood
sampling during the first trimester, and the second screening test
was done as soon as possible after the sample in the first test was
foundtobe positive.Iftheresultofthefirstscreeningtest isnegative,
the test is reported as negative; if a result of the first screening test is
positive, the same sample is tested using the second screening test. If
the result of the second test is negative, the test is reported as
negative; if the result of the second test is positive, confirmatory tests
using Western blots and NAT are conducted.
Statistical Analysis
Specificity was calculated using a combination of Western blots
and NAT as the gold standard. Confidence intervals (CIs) were
estimated using approximation to the normal distribution.
Research Ethics
This study was jointly approved by the ethics committees at the
two maternity hospitals and the Kanagawa Prefectural Institute of
Public Health. The verbal informed consent for study participa-
tion including screening and confirmatory tests was obtained from
study participants and recorded by the physician on a separate
study-participation sheet. As blood samples used in this study had
been collected as routine tests and thus no additional invasive
action was required for participants, the committees approved this
procedure according to the Ethical Guideline of the Ministry of
Health, Labour and Welfare of Japan. All links between the test
results and personal identifiers were removed and were known
only to the physicians in charge of the subjects.
Results
Comparative Assays
The sensitivities of the Enzygnost HIV Integral and VIDAS
HIV DUO Quick in the early phase of infection were compared
using 10 HIV-1 seroconversion panels. HIV infection was detected
with the VIDAS HIV DUO Quick earlier than with the
Enzygnost HIV Integral in eight out of ten panels; the interval
was an average of 4.5 days (Table 1). Next, the antigen detection
sensitivities of the two tests were compared using serial twofold
dilutions of three HIV-1 antigen samples (PRB936-04, PRA 201-
05, and PRA201-17). The VIDAS HIV DUO Quick was 16–32
times more sensitive than the Enzygnost HIV Integral (Table 2).
Results of HIV Testing
Of the 6,461 study participants, 27 (0.42%) showed positive
results for the first screening test performed using the Enzygnost
HIV Integral. When the positive samples were tested with the
second screening test performed using the VIDAS HIV DUO
Quick, only one sample exhibited a positive reaction and the
remaining 26 samples were nonreactive. When the samples that
tested positive in the first screening were tested using confirmatory
Western blots and NAT, only one sample was positive and the
HIV Screening Algorithm
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confirmatory test results were positive was the same as the one
whose second screening test result was positive. The sample from
this subject was positive with an HIV-1 Western blot, indetermi-
nate with an HIV-2 Western blot, and HIV-1 positive on HIV
typing. As for the signal-to-cutoff (S/CO) ratio on the Enzygnost
HIV Integral used as the first screening test, the one positive
sample was 6.47; of 26 false-positive samples, two were $6.0, four
were 2.0–6.0, and 20 were ,2.0. Western blots of the 26 negative
samples showed that one was indeterminate with both HIV-1 and
HIV-2 Western blots (S/CO ratio, 1.24), two were indeterminate
with only HIV-1 Western blots (0.92 and 5.87), and one was
indeterminate with only HIV-2 Western blots (6.34): all were
negative on HIV typing.
In the standard protocol using a single screening test, the false-
positive rate was 0.40% (95% CI, 0.25–0.56%), and the positive
predictive value was 3.7%. However, when an additional
screening test was introduced, the overall specificity of the
screening was improved dramatically, and the above values were
changed to 0% and 100%, respectively.
Discussion
According to the guideline for prevention of mother-to-child
transmission of HIV in Japan [7], women who are found to be
pregnant at hospital are generally tested for HIV during the first
Figure 1. Comparison of the results obtained by two HIV testing algorithms. A, algorithm containing single test screening. B, algorithm
containing serial two-test screening.
doi:10.1371/journal.pone.0009382.g001
Table 1. Test performance to detect bleed day with first
positive result using seroconversion panel members.
Panel
Bleed day with first
positive result
Difference in bleed
days between the
two tests
Enzygnost HIV
integral
VIDAS HIV DUO
Quick
PRB936 12 12 0
PRB937 21 14 7
PRB938 3 0 3
PRB939(E) 21 16 5
PRB945 13 13 0
PRB951 11 8 3
PRB952 17 10 7
PRB953 10 3 7
PRB954 21 17 4
PRB955 12 3 9
Average 4.5
doi:10.1371/journal.pone.0009382.t001
HIV Screening Algorithm
PLoS ONE | www.plosone.org 3 February 2010 | Volume 5 | Issue 2 | e9382trimester, and HIV-positive women are treated with antiretroviral
therapy from the second trimester and intravenous administration
of zidovudine during labor. Babies are treated with zidovudine
syrup for 6 weeks after birth. Testing of women in labor is
performed with a rapid antibody test, and positive women are
regarded as infected with HIV, and zidovudine administration was
initiated to the woman and a newborn baby.
Routine HIV testing for pregnant women has been underway
since 1999 in Japan. A questionnaire survey conducted in 2003
reported that only 7 out of 82,290 pregnant women were
diagnosed as being HIV-1 positive [8]; thus, the prevalence was
0.009%, which is extremely low compared with 0.15%–5% in the
United States [9]. This survey also reported that the false-positive
rate of screening tests was 0.094%, and that its positive predictive
value was 8.3%. These values agree with those obtained in the
present study. Since about one million pregnant women are tested
each year in Japan, about 1,000 women are probably notified of
false-positive results after screening tests.
Identifying such false-positive results using confirmatory testing
is not easy. With the introduction of fourth-generation EIA tests
for screening, the confirmatory test sequence has become very
complicated. Because these EIA tests can detect antibodies against
HIV-1 and HIV-2 as well as HIV-1 antigen, the confirmation of
positive results requires an HIV-1 Western blot, HIV-2 Western
blot, and NAT for HIV-1 RNA. Western blots result in a high
percentage of indeterminate results [10]. Furthermore, even if the
result of HIV-2 Western blot is negative, HIV-2 infection cannot
be denied because the sensitivity of HIV-2 Western blots is lower
than those of EIA tests for the detection of HIV-2 antibody.
Therefore, even if samples are shown to be negative with any one
of the three tests, the subjects should be retested one month later.
Consequently, once a pregnant woman is assigned a positive
screening test result by a false-positive reaction, she must undergo
two rounds of confirmatory tests in one month.
HIV-tested pregnant women have been reported to encounter
various problems associated with false-positive screening results
[3,9–13]. In Japan, pregnant women who were notified of positive
screening results felt strong anxiety and depression while waiting
for the results of the confirmatory tests; some of the women
became suspicious of their partners, and some considered abortion
or divorce [3]. One woman was notified of an HIV positive result
by her clinician without receiving sufficient explanation about the
screening testing; later, when confirmatory testing showed that she
was HIV negative, she became upset and untrusting of medical
services [3]. Such emotional disturbances have been reported in
other countries [9,10]. However, the situation in Japan may be
somewhat different from those in most of developed countries
because the HIV prevalence (0.009%) is extremely low. Most
obstetricians have never treated an HIV-infected individual and
thus have little chance of learning HIV infection and its diagnosis.
Therefore, it is the most important to help obstetricians to
understand the nature of HIV testing and to provide clients with
counseling and information, including the high frequency of false-
positive results in screening testing and the necessity of
confirmatory testing to obtain a decisive result.
As an alternative approach to resolving these problems from a
technical point of view, we proposed a screening algorithm
consisting of serial two fourth-generation enzyme immunoassays to
reduce the number of false-positive test results. When this
algorithm was applied to the 6,461 pregnant women who
participated in this study, the specificity of screening was improved
from 99.6% to 100% and the positive predictive value was
improved from 3.7% to 100%, compared with the standard
protocol. Although the two screening tests were conducted at
separate reference laboratories in this clinical trial, these tests can
be sequentially done at the same place. By applying this algorithm
to clinical settings, many uninfected clients would not need to
receive confirmatory tests and thus would not be subjected to
emotional turmoil while waiting for their confirmatory test results.
In addition, because extensive confirmatory tests and repeat visits
are not required, it results in cost savings. Although the number of
participants in this study is limited, the increase in specificity and
positive predictive value can likely be extrapolated to a larger
population of pregnant women.
It has been suggested that false positives may be caused by
alloantibodies resulting from pregnancy, transfusions, or trans-
Table 2. Antigen detection limits by antigen-antibody combined detection tests using 3 antigen positive specimens in the panels.
Panel No.
Antigen-antibody combined
detection test 1:1 1:2 1:4 1:8 1:16 1:32 1:64 1:128
PRB936-04 VIDAS HIV DUO Quick TV
1 9.84 5.55 3.01 1.53 0.89 0.47 0.32 0.21
Result POS POS POS POS POS POS POS NEG
Enzygnost HIV Integral S/CO
2 4.52 2.32 0.90 0.64 0.38 0.21 NT
3 NT
Result POS POS IND NEG NEG NEG NT NT
PRA201-05 VIDAS HIV DUO Quick TV 3.27 1.69 0.98 0.56 0.31 0.23 0.15 0.13
Result POS POS POS POS POS NEG NEG NEG
Enzygnost HIV Integral S/CO 1.58 0.63 0.34 0.19 NT NT NT NT
Result POS NEG NEG NEG NT NT NT NT
PRA201-17 VIDAS HIV DUO Quick TV 2.98 1.58 0.84 0.45 0.28 0.22 0.17 NT
Result POS POS POS POS POS NEG NEG NT
Enzygnost HIV Integral S/CO 1.77 0.78 0.36 0.19 NT NT NT NT
Result POS NEG NEG NEG NT NT NT NT
POS, positive; NEG, negative; IND, indeterminate.
1TV, test value. TV,0.25 was judged as negative, and TV§0.25 was judged as positive.
2S/CO, signal-to-cutoff ratio.
3NT, not tested.
doi:10.1371/journal.pone.0009382.t002
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study participants, which may influence testing results. The false-
positive rate of Enzygnost HIV Integral in this study was 0.40%,
which is within a range (0.3%–0.8%) of previously reported false-
positive rate of this kit [14–16]. Therefore, it is unlikely that the
false-positive rate observed in the first screening was influenced by
medical conditions including pregnancy and testing factors such as
quality control and performance in the reference laboratory.
The proposed protocol is characterized by a specificity-optimized
serial two-test algorithm. When the specificity is optimized, a serial
testing algorithm and a parallel testing algorithm are equally
sensitive and specific. A parallel testing algorithm is time-saving for
diagnosis of HIV infection; a serial testing algorithm is cost-effective
and less laborious. Because the HIV prevalence was very low in
Japan, most of positive results are due to false positives of the tests.
Furthermore, simultaneous two screening tests are not covered the
public medical insurance. We think that a serial testing is more
acceptable in our country.
The order of the two tests could be determined based on several
factors including throughput, cost, labor intensity, sensitivity, and
specificity. In this study, the VIDAS HIV DUO Quick was used as
the second screening test because it is less suitable for large-scale
testing and has been shown to be more sensitive in the early phase of
infection than the Enzygnost HIV Integral. The latter characteristic
may help to reduce the number of false-negative results in the second
screening. However, it shouldbe noted that the overallsensitivity and
specificity of a serial screening algorithm are determined only by the
combination of the two tests and their order is irrelevant.
Inevitably, the sensitivity of the serial screening algorithm is
lower than those of the individual tests employed therein, and the
specificity is higher. However, if the two tests employed are highly
sensitive, the decrease in sensitivity is expected to be marginal and
less than the difference among currently available screening tests
[17]. On the other hand, the adoption of the algorithm improves
the specificity dramatically. Theoretically, the sensitivity of the first
test should be as high as possible to ensure the detection of the
largest possible number of HIV-positive samples [17,18]. Howev-
er, recent EIA tests have undergone dramatic improvements, and
most fourth-generation tests have achieved nearly 100% sensitivity
on HIV-1/2 reference positive samples and are capable of
detecting early infection two to seven days after NAT
[15,19,20]. The ranking of these tests on seroconversion panels
varies among individual panels [15,19,20], and is probably
indecisive for field samples. Therefore, as long as two highly
sensitive fourth-generation tests are used, which test is more
sensitive may not be the primary determinant of the test order.
We should be cautious in applying the proposed screening
algorithm to other health-care settings. In clinical settings
specializing in HIV infection, clinicians are likely to diagnose
their patients with a high sensitivity and specificity. The HIV-1
prevalence in this setting would likely be relatively high, and the
clinicians would be well trained with regard to providing
counseling and information regarding HIV testing. In such a
setting, the present algorithm may not be required. Meanwhile,
voluntary HIV counseling and testing have been implemented
chiefly in public health centers on a free-of-charge basis, and rapid
antibody tests are widely used for screening testing. The sensitivity
and specificity of third-generation rapid test were shown to be
lower than those of fourth-generation EIA tests [16,17]. In these
cases, the introduction of a fourth-generation EIA test as the
second screening would not miss true positive samples and would
enable a great reduction in false-positive screening samples.
As the performance of HIV diagnostic tools evolve, the
diagnostic algorithms should also be changed to be accurate as
well as beneficial to the clients, and they need to be developed
specifically for individual health-care settings. The screening
algorithm presented in this study provides improved specificity
and positive predictive value, and cost savings, which is suitable
and beneficial for HIV testing in low prevalence settings such as
for maternity hospitals in Japan.
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